KEGG   DRUG: Dasabuvir, ombitasvir, paritaprevir and ritonavir
Entry
D10582            Mixture   Drug                                   
Name
Dasabuvir, ombitasvir, paritaprevir and ritonavir;
Viekira pak (TN)
Product
Component
(Dasabuvir sodium hydrate [DR:D10581] | Dasabuvir [DR:D10553]), (Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]
Class
Antiviral
 DG03198  Anti-HCV agent
Metabolizing enzyme substrate
 DG02918  CYP2C8 substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
  DG01522  CYP3A4 inhibitor
 DG02887  UGT1A1 inhibitor
Transporter substrate
 DG01665  ABCB1 substrate
 DG01913  ABCG2 substrate
 DG02856  SLCO1B1 substrate
 DG02932  SLCO1B3 substrate
Transporter inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
ATC code: J05AP52
Product: D10582<US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Comment
Dasabuvir is an inhibitor of UGT1A1 and P-glycoprotein (P-gp). It is metabolized by CYP2C8 and it is a substrate for P-glycoprotein (P-gp).
Ombitasvir is an inhibitor of UGT1A1, and it is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Paritaprevir is an inhibitor of UGT1A1, and it is an inhibitor of the following transporters: OATP1B1 and OATP1B3. It is metabolized by CYP3A4 and it is a substrate for P-glycoprotein (P-gp).
Ritonavir is an inhibitor of CYP3A4 and P-glycoprotein (P-gp). It is metabolized by CYP3A and it is a substrate for P-glycoprotein (P-gp).
Target
HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
HCV NS5B [KO:K22472]
RNA-directed DNA polymerase
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko05160  Hepatitis C
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], CYP2C8 [HSA:1558]
Transporter: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCB1 [HSA:5243], ABCG2 [HSA:9429]
Interaction
CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Enzyme inhibition: UGT1A1 [HSA:54658]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir
      D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir <US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Dasabuvir/ Ombitasvir/ Paritaprevir/ Ritonavir
    D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG01633  CYP3A/CYP3A4 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
 Metabolizing enzyme inhibitor
  DG02852  CYP3A/CYP3A4 inhibitor
   DG01522  CYP3A4 inhibitor
    D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG02887  UGT1A1 inhibitor
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
 Transporter substrate
  DG01665  ABCB1 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG01913  ABCG2 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG02856  SLCO1B1 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG02932  SLCO1B3 substrate
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
 Transporter inhibitor
  DG02862  ABCG2 inhibitor
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG02865  SLCO1B1 inhibitor
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
  DG02907  SLCO1B3 inhibitor
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
Drug classes [BR:br08332]
 Antiviral
  DG03198  Anti-HCV agent
   D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HCV NS3/4A inhibitor
    D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10582
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10582
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10582
 Drug transporters
  D10582
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D10582
Other DBs
PubChem: 254741544
ChEBI: 85177
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system